STRO-004
Protein Target: Tissue Factor, TF
- Solid Tumors
- Undisclosed indication
Sutro Biopharma
Most recent annual filing: 2026-03-23
- STRO-004 toplinemid-2026STRO-004 topline, mid-2026, thesis-defining
- STRO-006 IND filing3Q 2026STRO-006 IND filing, 3Q 2026, notable
- STRO-227 IND filing2H 2026STRO-227 IND filing, 2H 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
STRO-227
Protein Target: PTK7, Protein Tyrosine Kinase 7
STRO-006
Protein Target: ITGB6, integrin alpha v beta 6
Technology platforms
XpressCF · Vaxcyte
Cell-free protein synthesis platform enabling rapid production of complex biologics including ADCs, iADCs, bispecific ADCs, and dpADCs for oncology; also licensed to Vaxcyte for infectious disease vaccine development
XpressCF+ · Astellas
Site-specific conjugation platform enabling non-natural amino acid incorporation and precise dual-payload conjugation for homogeneous ADCs, iADCs, bispecific ADCs, and dpADCs in oncology
XpressCF
Cell-free protein synthesis platform (XpressCF® and XpressCF+®) used to generate site-specific and novel-format antibody-drug conjugates for oncology programs including STRO-004, STRO-006, and STRO-227
Discontinued (2)
- luveltamab tazevibulin — undisclosed · strategic decision to deprioritize additional investment; development has since been terminated
- STRO-003 — undisclosed · Ipsen decided not to advance STRO-003 program following review of new data and ROR1 landscape; license terminated August 2025
Biotech Distilled coverage (2)
- 2026-08-13 UPDATE: Sutro Biopharma (STRO) - The Binary Event Landed 🔒 Paid
- 2026-04-27 Sutro Biopharma (STRO) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.